Research notes
Stay informed with the most recent market and company research insights.

Research Notes
Piercing through the gloom
SkinKandy
November 19, 2026
SK1 reported a solid trading update for the first 19 weeks of FY27, with total sales up 21%, continuing the strong momentum from the first 7 weeks. Gross margins remain strong and are tracking in line with FY26. >Store rollout continues at pace, with 9 stores opened to date and SK1 re-affirmed guidance of 18-20 stores in FY27 in ANZ. Internationally, South Africa is progressing well with a country manager appointed and several sites in negotiation. Management is targeting entry in 2H FY27. >We have made no changes to our forecasts, our valuation lifts to $3.20 (from $3.10) driven by higher peer multiples. We maintain our BUY recommendation.
Model update post AGM
IPH Limited
November 19, 2026
IPH’s AGM trading update showed Underlying EBITDA down ~13% for the four months to October (FYTD). Whilst FX remained a headwind in the period, key markets of Asia and Canada appear to be stabilising to a degree. However, this was offset by a softer ANZ market which continues to weigh on the overall business performance. >Revenue fell 8.4% to A$221.5m and Underlying EBITDA 13.4% to A$62.6m. On a like-for-like (LFL) basis (ex FX), revenue fell 1.2% and Underlying EBITDA 4.2%, against LFL growth of 1.6% and 2.9% in FY26. >By market: ANZ LFL revenue fell 7.3% and LFL Underlying EBITDA 13.5%, worse than FY26 (-4.2% and -7.2%). Excluding self-filed provisionals, the Australian patent market fell 3.5% and IPH’s filings 6.1%. The market has turned negative and US PCT filings remain subdued. Canada: LFL revenue rose 3.7% and LFL Underlying EBITDA 2.8%, down from 5.8% and 11.8% in FY26. CIPO workflows have recovered. Asia: LFL revenue fell 0.5% and LFL Underlying EBITDA 1.7%, with lower filings mainly in Singapore, where IPH’s filings had already fallen 12.6% in FY26; management cites a strong margin and a good new business pipeline. >Strategy a focus. IPH management noted its priorities are restoring organic growth through client management, business development and referrer relationships. We expect an update on the strategic review in due course. >We lower our FY27-FY29 EBITDA estimates by 6-8%. Our price target is lowered to A$4.35 (from A$4.65).
1H27 result reinforces portfolio positioning
Infratil
November 19, 2026
IFT’s 1H27 result and outlook both came in slightly ahead of our expectations with operating performance resulting in a small upgrade to FY27 EBITDA guidance. NAV (post fees) lifted 15% YoY to NZ$17.94 and the dividend lifted 2% YoY. >Following recent share price weakness we upgrade to a BUY recommendation.
Rebalancing the ledger
ReadyTech Holdings
November 18, 2026
RDY has agreed to sell its non-core Managed Payroll Services business for A$7.0m cash consideration (an implied 0.9x FY27 revenue / ~5.4x FY27 Cash EBITDA), with proceeds funding a buyback of up to A$5.0m. >FY27 revenue guidance re-based to A$120-124m for the core business (previously A$128-132m including the divested business). Underlying cash EBITDA margin guidance of 15-17% is unchanged. >We see this as a positive step in delivering on its strategy around improved portfolio management and capital allocation, which should ultimately deliver improved earnings momentum over the medium term. We retain our SPECULATIVE BUY rating with a revised A$2.20 target price (previously A$2.25).
IPART final report: a smaller cut, but still a cut
PEXA Group
November 18, 2026
IPART’s final report recommends a ~16% cut to PEXA Exchange’s regulated revenue from FY28, with CPI increases allowed after that. This would take ~A$50m off FY28 revenue, better than the draft report, which proposed a ~20% cut and a A$70m revenue hit. >ARNECC will now carry out its own assessment and run a formal consultation, with a final decision on any changes to ELNO service fees expected in 2H FY27. >Overall, lobbying has meaningfully reduced the price cut (A$50m vs A$70m in the draft), but the new pricing regulation is still a clear negative for PXA’s revenue, in our view. >Our forecasts had only partly reflected the draft report’s A$70m cut, so the smaller final cut lifts our FY28F and FY29F EPS by ~8%. Our target price rises to A$7.34 (from A$7.03). We maintain our HOLD rating.
Cross-sell driving ACV progress
Catapult Sports
November 18, 2026
CAT's 1H27 result was in line with consensus ACV and ahead at the Management EBITDA line. Closing ACV of US$145.2m was +25% on the pcp on a constant currency (c/c) basis (+18% ex-acquired ACV). Management EBITDA of ~US$16m (19.7% margin) was 3% above consensus. Performance metrics were sound (e.g. churn under 5%, Rule of 40 at 38%) and FCF (ex-transaction costs) was US$9.3m (vs US$8.2m in the pcp). >We make several adjustments to our estimates factoring in the 1H27 result, resulting in 6-8% downgrades to Management EBITDA over FY27-FY29F. We forecast ~US$165m in revenue and ~US$32m in Management EBITDA in FY27. Our price target is lowered to A$5.05 (from A$5.40) on these changes. We maintain our Buy recommendation.
A weak 1H27; reset underway but it will take time
Webjet Group Limited
November 18, 2026
WJL’s 1H27 result was weak and below expectations (underlying EBITDA A$7.0m, -51%), impacted by a weak trading environment, Virgin Australia’s commission cuts, the non-repeat of 1H26’s higher-than-usual variable revenue and lower conversion following website changes. New CEO Nicole Sheffield was candid: “This is not a good result… some of it was the market and some of it was us”. >No FY27 guidance was provided and 2H27 conditions are expected to remain uncertain. 2H27 has headwinds too, with a full six months of the lost Virgin Australia commission and the RBA’s card surcharging changes (from 1 October 2026; ~A$4m annualised). WJL is targeting A$10m of annualised cost savings (fully realised in FY28), but the CEO warned there is no quick fix. >We have materially lowered our FY27/28 EBITDA forecasts (-26.6%/-8.1%). We retain our HOLD rating with a new price target of A$0.30 (was A$0.40). In the absence of corporate activity, shareholders will need to be patient given the current challenges WJL needs to overcome.
Investing in book growth now for earnings later
Solvar
November 18, 2026
SVR’s 1Q27 trading update has highlighted a sustained acceleration in the group’s loan book growth, with the Australian loan book up 18.2% yoy driven by record originations of $163.9m (+72.7% yoy), taking the group’s book to ~$1.0bn. >FY27 remains a year of investment, with SVR flagging that upfront customer acquisition costs to support growth, investment in digital transformation, and a tougher macro backdrop will see FY27 Normalised NPAT of ~$21.0m (vs. MorgF $28.5m). Improved productivity benefits from FY27 investment are expected to flow through to NPAT in FY28 (with SVR targeting >$30m). >We cut our FY27/28 NPAT forecasts by -25%/-3% respectively, resulting in a revised price target of $1.65/sh. Overall, we look to SVR’s return to book growth as the key driver of earnings momentum into FY28-29, which should be further supported as near-term macro conditions ease. We therefore move to a BUY rating.
Coffer raid rescinded
Microba Life Sciences
November 18, 2026
Genetic Signatures (GSS) has walked away from the merger after Microba flagged it can’t fund completion without fresh capital. MAP has been in voluntary suspension since 17 Nov. >From the perspective of MAP, we never saw the deal as being about access to GSS’s 3base technology. It was about the balance sheet, and with that gone MAP is left in a precarious spot. >In our view, MAP faces real going concern risk without the merger or access to further capital. MAP remains in suspension to explore its options for alternative funding. We await further details around the outcome of this process. Until then, our recommendation and target price are under review.
Model update: Same scans, sooner recognition
Artrya
November 18, 2026
We have revised our revenue recognition assumptions. We previously modelled revenue waiting for the cash to land, whereas we now book at point of scan and the payment lag moves to the balance sheet. >FY27 revenue lifts to A$2m (from A$0.1m) and FY28 to A$12.9m (from A$3.4m). Same scans, same demand, just earlier on the P&L. None of this comes from HonorHealth, AYA’s new five-year Arizona contract, which we see as an early signal of things to come rather than a reason to lift numbers yet. >Pulling revenue forward is a modest positive for our valuation struck off FY31 sales. We maintain our Speculative Buy rating with an increased target price of A$4.70 (previously A$4.25).
News & insights
November 19, 2026
November 17, 2026
min read
Agricultural Investing Trends: Seasonal Supply Through an El Niño Cycle
Scott Fraser (AR: 001254347)
Financial Adviser
November 12, 2026
November 12, 2026
min read
Financial services internship: what one QUT student learned at Morgans
Morgans Opinion
Opinion
November 11, 2026
November 10, 2026
min read
Macro Monthly Market: A Worldly Lens - October 2026
Scott Fraser (AR: 001254347)
Financial Adviser


